Table 5 Sensitivity analysis based on drug treatment before trials

Excluding the studies with non-responders to other sulfonylureas

BMI

10

988

0.50

92%

<0.00001

-0.06 [-0.53, 0.40]

0.79

SBP

5

615

0.22

86%

<0.0001

0.39 [-0.06, 0.83]

0.09

DBP

5

615

0.23

87%

<0.00001

0.34 [-0.12, 0.79]

0.15

FPG

12

1314

0.04

48%

0.03

0.01 [-0.15, 0.17]

0.91

HbA1c

11

1246

0.03

46%

0.05

0.04 [-0.12, 0.19]

0.65

PPBS

9

802

0.27

85%

<0.00001

-0.32 [-0.69, 0.06]

0.10

TC

9

887

0.16

79%

<0.0001

0.33 [0.03, 0.63]

0.03

HDL

9

887

0.24

85%

<0.00001

0.11 [-0.25, 0.46]

0.56

LDL

6

702

0.02

29%

0.21

0.35 [0.16, 0.53]

0.0002

TG

9

887

0.05

54%

0.03

0.26 [0.05, 0.46]

0.01

FINS

8

722

0.58

92%

<0.00001

0.11 [-0.44, 0.67]

0.69

Excluding the studies with participants who used other anti-diabetic drugs before RCTs

BMI

6

687

0.05

56%

0.04

0.27 [0.03, 0.51]

0.03

SBP

3

444

0.22

87%

0.0004

0.60 [0.03, 1.16]

0.04

DBP

3

444

0.29

90%

<0.0001

0.52 [-0.12, 1.16]

0.11

FPG

8

989

0.07

66%

0.004

-0.03 [-0.26, 0.19]

0.78

HbA1c

7

921

0.05

61%

0.02

-0.00 [-0.22, 0.22]

1.00

PPBS

5

477

0.54

92%

<0.00001

-0.60 [-1.28, 0.08]

0.08

TC

6

687

0.18

82%

<0.0001

0.38 [0.00, 0.76]

0.05

HDL

6

687

0.12

76%

0.0009

-0.14 [-0.46, 0.19]

0.41

LDL

4

572

0.04

56%

0.08

0.30 [0.05, 0.56]

0.02

TG

6

687

0.00

0%

0.74

0.13 [-0.02, 0.28]

0.10

FINS

5

483

0.53

92%

<0.00001

0.43 [-0.24, 1.10]

0.21